Abstract: The application relates to compositions containing 2?-FL and DFL for use in a method of reducing pain and/or the perception of visceral pain in a non-infant human.

Abstract: The present invention relates to compositions comprising a mix of human milk oligosaccharides consisting of 2?-fucosyllactose and difucosyllactose, for use in the reduction of pain and/or perception of pain in an infant or in a young child. The compositions are particularly effective in the restoration of the sensitivity of the bi-directional pain transmission pathways in the gut-brain axis to normal levels. The compositions are in particular useful in reducing abdominal pain, such as pain associated with gastrointestinal discomfort, functional gastrointestinal disorders, and/or gastrointestinal diseases and consequently also contribute to reducing the crying periods and to improving the quality of sleep, the general quality of life, the mood, the playfulness, the temperament and/or the happiness of the infants and young children.

Abstract: The present invention relates to methods for producing compositions comprising secretory IgA and one or more probiotics. In particular, the invention relates to methods for producing compositions in which the secretory IgA and one or more probiotics are associated. The invention also relates to compositions obtainable by the methods and uses of the compositions, for example in reducing or preventing a non-viral infection and/or inflammation.

Abstract: The present invention relates to a nutritional composition comprising at least two human milk oligosaccharides, for use to decrease the concentration of detrimental proteolytic metabolites (e.g. branched short chain fatty acids) in the digestive tract in an infant or a young child.

Abstract: The present invention relates to a nutritional composition comprising at least three human milk oligosaccharides, for use to increase butyrate production in the digestive tract in an infant or a young child. The production increases with the HMOs blend complexity.

Abstract: The present invention relates to a nutritional composition comprising at least three human milk oligosaccharides, for use to increase butyrate production in the digestive tract in an infant or a young child. The production increases with the HMOs blend complexity.

Abstract: The present invention relates to a nutritional composition comprising at least two human milk oligosaccharides, for use to decrease the concentration of detrimental proteolytic metabolites (e.g. branched short chain fatty acids) in the digestive tract in an infant or a young child.

Abstract: A method, in one embodiment, includes administering to a non-infant human an effective amount of a combination of the human milk oligosaccharides (“HMO”s) 2?-FL and DFL, where the amount of the combination of HMOs is effective for modulating the microbiota of the non-infant human and reducing one or more post-treatment condition such as pain and/or a perception of visceral pain in the non-infant human.

Abstract: The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide, for use in reducing and/or controlling food intake in an infant or a young child, and/or for use in promoting a healthy growth in an infant or a young child.

Abstract: Probiotics and ways to increase their effectiveness are provided. One embodiment of the present invention relates to a combination of probiotics with SIgA and possible uses of this combination. For example a use of a composition comprising SIgA and at least one probiotic for the preparation of a product to treat or prevent inflammation is disclosed.

Abstract: The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide and atleast one N-acetylated oligosaccharide, for use in reducing and/or avoiding excessive fat mass accumulation in an infant or a young child and/or for use in preventing the related later in life health disorders like later in life obesity and related comorbidities.

Abstract: The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide,for use in reducing and/or controlling food intake in an infant or a young child, and/or for use in promoting a healthy growth in an infant or a young child.

Abstract: Probiotics and ways to increase their effectiveness are provided. One embodiment of the present invention relates to a combination of probiotics with SIgA and possible uses of this combination. For example a use of a composition comprising SIgA and at least one probiotic for the preparation of a product to treat or prevent inflammation is disclosed.

Abstract: The present invention relates generally to the field of nutrition, health and wellness. In particular the present invention relates to probiotics and ways to increase their effectiveness. One embodiment of the present invention relates to a combination of probiotics with SIgA and possible uses of this combination. For example a use of a composition comprising SIgA and at least one probiotic for the preparation of a product to treat or prevent inflammation is disclosed.

Abstract: Ways to increase the effectiveness of probiotics are disclosed. One embodiment relates to a combination of probiotics with secretory IgA and possible uses of this combination. For example, a method of using a composition containing secretory IgA and at least one probiotic to prepare a product to treat or prevent infection is disclosed.

Abstract: Ways to increase the effectiveness of probiotics is disclosed. One embodiment relates to a combination of probiotics with secretory IgA and possible uses of this combination. For example, a method of using a composition comprising secretory IgA and at least one probiotic to prepare a product to treat or prevent infection is disclosed.

Abstract: Ways to increase the effectiveness of probiotics is disclosed. One embodiment relates to a combination of probiotics with secretory IgA and possible uses of this combination. For example, a method of using a composition comprising secretory IgA and at least one probiotic to prepare a product to treat or prevent infection is disclosed.

Abstract: A nutritional composition is proposed comprising a probiotic and milk fat globule membrane (MFGM) wherein the MFGM and the probiotics mutually potentiate their respective effects and promote complementary beneficial protective mechanisms that reflect physiological synergy. The nutritional composition can be an infant formula, infant cereals, baby food or health care nutritional product. The synergistic effect can include promoting immune maturation and/or immune education and/or reducing inflammation and/or treating or preventing disease or infections.

Abstract: The present invention relates generally to the field of nutrition, health and wellness. In particular the present invention relates to probiotics and ways to increase their effectiveness. One embodiment of the present invention relates to a combination of probiotics with secretory IgA and possible uses of this combination. For example a use of a composition comprising secretory IgA and at least one probiotic for the preparation of a product to treat or prevent infection is disclosed.

Abstract: The present invention addresses the problem of inactivation of bioactive components in milk during pasteurization for preservation. The invention discloses a method of pulsed electric field (PEF) treatment of whole milk, skimmed milk, semi-skimmed milk or whey, or other liquid compositions comprising milk components or fractions. The invention is based on the finding that by selecting one or more specific process parameters, such as the PEF treatment chamber design, the specific energy applied, the field strength, pulse type, start temperature, it is possible to effectively eliminate microorganisms from the composition while conserving the activity of bioactive components in the composition.